Home ➜ Managed Lab Services ➜ What It Takes to Build and Run An In-House Genetic Lab

What It Takes to Build and Run An In-House Genetic Lab

Aug 23, 2026

Large physician groups with substantial genetic testing volume may eventually reach a point where bringing eligible testing in-house becomes a serious strategic option. 

The opportunity can be significant. Genetic testing can move closer to the physicians ordering it, expand the organization’s laboratory capabilities, and become part of a broader physician-owned lab strategy. It can also operate at a very different financial scale from more routine molecular testing. 

That naturally draws attention to the build: which tests to perform, how much volume exists, what equipment is needed, how the lab should be staffed, and what reimbursement the organization might expect. 

Those are important questions, but they do not describe the full operating decision. 

A high-complexity genetic lab depends on clinical oversight, specialized personnel, testing processes, compliance, reimbursement, reporting, physician participation, and day-to-day management working together after launch. A practice can acquire every component needed to establish the laboratory and still be left responsible for integrating the operation itself. 

The pro forma contains operating assumptions 

A genetic lab pro forma can make the opportunity look straightforward: expected testing volume multiplied by expected reimbursement, less the cost of building and operating the lab. 

A substantial amount of operating work sits inside those assumptions. 

The model assumes physicians will direct enough appropriate testing to the new lab. It assumes the laboratory will be able to process that testing correctly and consistently. It assumes the organization can bill for the testing successfully and convert expected reimbursement into collected revenue. Each of those assumptions depends on a different part of the operating model. 

Volume depends on physician behavior and staff execution. Testing depends on qualified personnel, appropriate oversight, validation, quality processes, equipment, workflows, and daily laboratory management. Financial performance depends on coding, payer requirements, claims management, denials, collections, and reporting. 

A spreadsheet can multiply volume by reimbursement in a cell. Operations have to make those assumptions real. 

This is where evaluating a genetic laboratory primarily as a capital project can leave an important part of the decision unresolved. The question is not only whether the economics justify establishing the lab. Leadership also has to understand what operating systems will be required to produce those projected numbers after testing begins. 

 

Genetics raises what the physician-owned model has to support 

Many of those operating requirements are already present in a physician-owned molecular laboratory, but genetics raises the level of specialization within those requirements. 

If an organization is already running molecular testing in-house, some existing infrastructure may provide a foundation. Laboratory space may be usable, although additional capacity may be needed. Existing LIS and EHR infrastructure may continue to support the genetic lab. The assumption that these operations translate easily into genetics can create false confidence in a business case that depends on a much more specialized operating model. 

CMS regulates laboratory testing through CLIA, with requirements tied in part to test complexity and specific qualifications applying to high-complexity laboratory personnel and oversight. 

Reimbursement also becomes a more specialized discipline. Genetic claims can involve requirements that are highly specific to the test and payer. CMS MolDX guidance, for example, requires particular molecular diagnostic claims to include the appropriate CPT code and DEX Z-Code identifier. 

For a physician group, those distinctions translate into more specialized laboratory leadership, personnel with relevant genetic experience, more complex instrumentation, validation work, testing processes, and quality systems appropriate to the assays being performed.  

A genetic lab stops at buildout with the familiar path 

The way genetic laboratories are commonly developed makes it easy to focus on buildout alone. 

A consultant may guide implementation. Instrument companies provide equipment. Laboratory professionals handle specialized clinical and technical work. Technology vendors support the LIS and integrations. Billing resources manage claims. Internal teams coordinate space, physicians, staff, and other organizational requirements. 

Each function requires expertise. The management issue appears in the connections between them. 

Staffing affects testing capacity. Validation and testing processes affect clinical performance. Physician ordering behavior determines whether anticipated volume reaches the lab. Reimbursement depends on what was ordered, documented, performed, coded, and submitted. Quality, compliance, reporting, and personnel requirements continue after implementation. 

When responsibility for those functions remains distributed, the physician group becomes responsible for making the laboratory perform as one cohesive system. 

With a genetic lab, the consequences can be significant. The organization has committed to a high-complexity testing model with specialized clinical requirements and a business case that depends heavily on utilization and reimbursement. Weak coordination in operations can affect the clinical capabilities and the financial assumptions at the same time. 

 

The financial opportunity depends on the reimbursement infrastructure 

Genetic testing can create a compelling financial case for the right organization, and women’s health provides a useful illustration of the difference in reimbursement scale. 

On the 2026 CMS Clinical Laboratory Fee Schedule, high-risk HPV molecular testing under CPT 87624 carries a reference payment amount of $35.09, while NIPT under CPT 81420 carries a reference payment amount of $759.05. These figures are useful only as an illustration of relative scale and does not establish coverage in a particular circumstance. (cms.gov). 

That difference helps show how the financial performance of a genetic lab can be overestimated before the path to successfully capture the reimbursement has been decided. 

High-complexity testing requires specialized revenue-cycle infrastructure capable of turning appropriate testing into properly billed and collected claims. Prior authorizations, Z-codes, documentation requirements, timely filing, denials, and appeals all by payer and test. Higher reimbursement also raises the cost of getting billing wrong. Genetic claims create more opportunities for mistakes that can delay or inhibit reimbursement, increase internal follow-up, and lead to confusing or unexpected bills for patients. 

For a genetic lab, reimbursement expertise must be part of the operating model from the beginning. Decisions about the revenue cycle ultimately determine whether the economics represented in the business case hold up after the lab has been built. 

 

A different path to physician-owned genetic testing 

Physician ownership does not require the practice to become the expert of every function behind a genetic laboratory. A fully managed model places responsibility for the connected infrastructure with one accountable lab partner over time. 

This is the model Phytest built for large physician groups and health systems that want to bring genetic testing in-house without being constrained by the hurdles to make it perform. Phytest owns the operations end to end while the practice participates through physician behavior, staff execution, and leadership reinforcement. The practice does not have to hire for, learn, or manage the buildout, clinical, operational, compliance, staffing, reporting, and reimbursement functions behind the lab. 

Genetic RCM is a particularly important part of that model. Phytest’s Genetic Lab Management service includes the entire revenue cycle operation rather than as a separate billing service added after the lab is built. Phytest’s unique and deep expertise in genetic reimbursement also allows for realistic assessments of when the opportunity for building a genetic lab is present and what it will need to actually perform.  

Our team helps organizations determine if the model is a fit by evaluating: 

  • Testing opportunity: Existing genetic utilization and specialty mix  
  • Clinical fit: Testing needs appropriate to the group’s specialties and patient population  
  • Payer viability: Reimbursement assumptions grounded in the actual payer environment  
  • Existing foundation: Space, systems, and current lab operations that can support t

See what your lab services are capable of

Start with a review of the tests being ordered today, and see what their value could be generating for your practice.

Explore all topics

Latest posts